Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Ross

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
Leukemia|May 21, 2021
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 studyFrancisco Cervantes, David M Ross, Atanas Radinoff, et al.
Blood Advances|May 8, 2026
Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AMLJulian Grabek, Jasmin M Straube, Leanne Cooper, et al.
British Journal of Haematology|March 28, 2019
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemiaDavid M Ross, Ilaria S Pagani, Yazad D Irani, et al.
JCO Oncology Practice|July 17, 2025
Clinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF AllianceKeita Kirito, Chul Won Choi, Than Hein, et al.
Blood|May 25, 2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M Ross, Susan Branford, John F Seymour, et al.
Blood|August 24, 2023
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapyIlaria S Pagani, Naranie Shanmuganathan, Phuong Dang, et al.
Blood|March 22, 2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLSusan Branford, David T Yeung, David M Ross, et al.
Science Advances|December 1, 2018
Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosisDenis Tvorogov, Daniel Thomas, Nicholas P D Liau, et al.
Blood Advances|December 21, 2021
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 studyJohn Mascarenhas, Francesco Passamonti, Kate Burbury, et al.
American Journal of Hematology|March 2, 2017
Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patientsDevendra K Hiwase, Deepak Singhal, Corinna Strupp, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
Leukemia|May 21, 2021
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 studyFrancisco Cervantes, David M Ross, Atanas Radinoff, et al.
Blood Advances|May 8, 2026
Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AMLJulian Grabek, Jasmin M Straube, Leanne Cooper, et al.
British Journal of Haematology|March 28, 2019
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemiaDavid M Ross, Ilaria S Pagani, Yazad D Irani, et al.
JCO Oncology Practice|July 17, 2025
Clinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF AllianceKeita Kirito, Chul Won Choi, Than Hein, et al.
Blood|May 25, 2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M Ross, Susan Branford, John F Seymour, et al.
Blood|August 24, 2023
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapyIlaria S Pagani, Naranie Shanmuganathan, Phuong Dang, et al.
Blood|March 22, 2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLSusan Branford, David T Yeung, David M Ross, et al.
Science Advances|December 1, 2018
Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosisDenis Tvorogov, Daniel Thomas, Nicholas P D Liau, et al.
Blood Advances|December 21, 2021
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 studyJohn Mascarenhas, Francesco Passamonti, Kate Burbury, et al.
American Journal of Hematology|March 2, 2017
Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patientsDevendra K Hiwase, Deepak Singhal, Corinna Strupp, et al.
Pageof 13